Unravelling Human Trypanotolerance: IL8 is Associated with Infection Control whereas IL10 and TNFα Are Associated with Subsequent Disease Development

Ilboudo, Hamidou; Bras-Gonçalves, Rachel; Camara, Mamadou; Flori, Laurence; Camara, Oumou; Sakande, Hassane; Leno, Mamadou; Petitdidier, Elodie; Jamonneau, Vincent; Bucheton, Bruno
November 2014
PLoS Pathogens;Nov2014, Vol. 10 Issue 11, p1
Academic Journal
In West Africa, Trypanosoma brucei gambiense, causing human African trypanosomiasis (HAT), is associated with a great diversity of infection outcomes. In addition to patients who can be diagnosed in the early hemolymphatic phase (stage 1) or meningoencephalitic phase (stage 2), a number of individuals can mount long-lasting specific serological responses while the results of microscopic investigations are negative (SERO TL+). Evidence is now increasing to indicate that these are asymptomatic subjects with low-grade parasitemia. The goal of our study was to investigate the type of immune response occurring in these “trypanotolerant” subjects. Cytokines levels were measured in healthy endemic controls (n = 40), stage 1 (n = 10), early stage 2 (n = 19), and late stage 2 patients (n = 23) and in a cohort of SERO TL+ individuals (n = 60) who were followed up for two years to assess the evolution of their parasitological and serological status. In contrast to HAT patients which T-cell responses appeared to be activated with increased levels of IL2, IL4, and IL10, SERO TL+ exhibited high levels of proinflammatory cytokines (IL6, IL8 and TNFα) and an almost absence of IL12p70. In SERO TL+, high levels of IL10 and low levels of TNFα were associated with an increased risk of developing HAT whereas high levels of IL8 predicted that serology would become negative. Further studies using high throughput technologies, hopefully will provide a more detailed view of the critical molecules or pathways underlying the trypanotolerant phenotype.


Related Articles

  • Relative Contribution of Interferon-gamma and Interleukin-10 to Resistance to Murine African Trypanosomosis. Namangala, Boniface; Noel, Wim; De Baetselier, Patrick; Brys, Lea; Beschin, Alain // Journal of Infectious Diseases;6/15/2001, Vol. 183 Issue 12, p1794 

    Presents a study which examined the role of interferon-gamma and interleukin-10 (IL-10) in the control of parasitemia and survival of mice infected with Trypanosoma brucei brucei. Materials and methods; Role of interferon-gamma as prerequisite for tumor necrosis factor and nitric oxide...

  • MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development. Stijlemans, Benoît; Leng, Lin; Brys, Lea; Sparkes, Amanda; Vansintjan, Liese; Caljon, Guy; Raes, Geert; Van Den Abbeele, Jan; Van Ginderachter, Jo A.; Beschin, Alain; Bucala, Richard; De Baetselier, Patrick // PLoS Pathogens;Sep2014, Vol. 10 Issue 9, p1 

    African trypanosomiasis is a chronic debilitating disease affecting the health and economic well-being of many people in developing countries. The pathogenicity associated with this disease involves a persistent inflammatory response, whereby M1-type myeloid cells, including Ly6Chigh...

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis. Chappuis, François; Udayraj, Nitya; Stietenroth, Kai; Meussen, Ann; Bovier, Patrick A. // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p748 

    Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kin, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with...

  • Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design. Pizarro, Juan Carlos; Hills, Tanya; Senisterra, Guillermo; Wernimont, Amy K.; Mackenzie, Claire; Norcross, Neil R.; Ferguson, Michael A. J.; Wyatt, Paul G.; Gilbert, Ian H.; Hui, Raymond // PLoS Neglected Tropical Diseases;Oct2013, Vol. 7 Issue 10, p1 

    Human African trypanosomiasis is a neglected parasitic disease that is fatal if untreated. The current drugs available to eliminate the causative agent Trypanosoma brucei have multiple liabilities, including toxicity, increasing problems due to treatment failure and limited efficacy. There are...

  • Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Pepin, Jacques; Khonde, Nzambi // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1284 

    Compares the effectiveness of 7 days of intravenous eflornithine with the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis. Use of a randomized controlled trial; Death of some patients during treatment; Difference in response to treatment...

  • Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Balasegaram, Manica; Harris, Steve; Checchi, Francesco; Hamel, Catherine; Karunakara, Unni // Bulletin of the World Health Organization;Oct2006, Vol. 84 Issue 10, p777 

    Objective In 2002-03, the Republic of the Congo increased the threshold separating stage 1 and 2 cases of human African trypanosomiasis (HAT) from a cerebrospinal fluid (CSF) white cell count of 5 cells/mm³ to 10 cells/mm³. We aimed to assess whether the increased threshold of 10...

  • Sleeping bug: scientists identify drug resistance mechanism.  // Africa Health;Mar2012, Vol. 34 Issue 3, p12 

    The article focuses on the study conducted by the researchers in Greta Britain, which reveals several ways by which parasite Trypanosoma brucei can resist drugs used in treating sleeping sickness.

  • New Clues to Sleeping Sickness.  // JAMA: Journal of the American Medical Association;1/2/2013, Vol. 309 Issue 1, p20 

    The article informs that a new research conducted by the scientists of Germany, Sweden and the U.S. has explained the structure of a key enzyme named "Trypanosoma brucei cysteine protease cathepsin B," (TbCatB) from the parasite that causes African trypanosomiasis or sleeping sickness.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics